

Ian A Cree

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3807/publications.pdf>

Version: 2024-02-01

138
papers

14,367
citations

76031

42
h-index

26792

111
g-index

142
all docs

142
docs citations

142
times ranked

16796
citing authors

#	ARTICLE	IF	CITATIONS
1	From Counting Mitoses to Ki67 Assessment: Technical Pitfalls in the New WHO Classification of Endocrine and Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2022, 33, 3-5.	5.2	11
2	Importance of Cytopathologic Diagnosis in Early Cancer Diagnosis in Resource-Constrained Countries. <i>JCO Global Oncology</i> , 2022, 8, e2100337.	0.8	6
3	Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. <i>Modern Pathology</i> , 2022, 35, 712-720.	2.9	17
4	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70
5	Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4322.	1.8	7
6	An introduction to the <sc>WHO</sc> 5th edition 2022 classification of testicular tumours. <i>Histopathology</i> , 2022, 81, 459-466.	1.6	32
7	<sc>WHO</sc> 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	1.6	39
8	The WHO Classification of Haematolymphoid Tumours. <i>Leukemia</i> , 2022, 36, 1701-1702.	3.3	53
9	<sc>WHO</sc> Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. <i>Histopathology</i> , 2022, 81, 447-458.	1.6	10
10	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2022, 82, 458-468.	0.9	212
11	Diagnosis of digestive system tumours. <i>International Journal of Cancer</i> , 2021, 148, 1040-1050.	2.3	36
12	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021, 148, 560-571.	2.3	32
13	Misleading terminology in pathology: lack of definitions hampers communication. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 425-430.	1.4	5
14	A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. <i>Journal of Pathology</i> , 2021, 254, 109-120.	2.1	5
15	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
16	Counting mitoses: Sl(ze) matters!. <i>Modern Pathology</i> , 2021, 34, 1651-1657.	2.9	61
17	Identification of potentially misleading terminology in the five currently published fifth edition who classification of tumours: an update. <i>Pathology</i> , 2021, 53, S23.	0.3	0
18	Response to letter to the editor by Moudgil-Joshi and Kaliaperumal. <i>Neuro-Oncology</i> , 2021, 23, 2122-2122.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e763-e772.	5.9	128
20	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. <i>Leukemia</i> , 2021, 35, 3040-3043.	3.3	42
21	The 2019 WHO classification of tumours of the digestive system. <i>Histopathology</i> , 2020, 76, 182-188.	1.6	1,952
22	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
23	Revising the WHO classification: female genital tract tumours. <i>Histopathology</i> , 2020, 76, 151-156.	1.6	84
24	How current assay approval policies are leading to unintended imprecision medicine. <i>Lancet Oncology</i> , The, 2020, 21, 1399-1401.	5.1	34
25	Invited commentary "WHO Classification of Tumours: How should tumors be classified? Expert consensus, systematic reviews or both?". <i>International Journal of Cancer</i> , 2020, 146, 3516-3521.	2.3	24
26	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
27	Commentary: Cancer research quality and tumour classification. <i>Tumor Biology</i> , 2020, 42, 101042832090754.	0.8	7
28	The 2019 World Health Organization classification of tumours of the breast. <i>Histopathology</i> , 2020, 77, 181-185.	1.6	395
29	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 500-522.	1.2	239
30	Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. <i>Histopathology</i> , 2020, 77, 340-350.	1.6	26
31	cIMPACT update 6: new entity and diagnostic principle recommendations of the cIMPACT Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	2.1	363
32	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019, 114, 128-136.	1.3	8
33	Cancer taxonomy: pathology beyond pathology. <i>European Journal of Cancer</i> , 2019, 115, 57-60.	1.3	10
34	Advisory Group recommendations on priorities for the IARC Monographs. <i>Lancet Oncology</i> , The, 2019, 20, 763-764.	5.1	70
35	Novel digital signatures of tissue phenotypes for predicting distant metastasis in colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 13692.	1.6	37
36	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786.	2.9	739

#	ARTICLE	IF	CITATIONS
37	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC Cancer, 2018, 18, 828.	1.1	19
38	Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer, 2017, 17, 10.	1.1	221
39	Validation of an NGS mutation detection panel for melanoma. BMC Cancer, 2017, 17, 150.	1.1	34
40	Simultaneous automatic scoring and coregistration of hormone receptors in tumor areas in whole slide images of breast cancer tissue slides. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 585-594.	1.1	6
41	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 5-20.	1.4	82
42	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. BMC Cancer, 2017, 17, 697.	1.1	94
43	Chronic tarsal conjunctivitis. BMC Ophthalmology, 2016, 16, 130.	0.6	5
44	Development and validation of a TaqMan Array for cancer mutation analysis. Pathogenesis, 2016, 3, 1-8.	0.8	2
45	Progress and potential of RAS mutation detection for diagnostics and companion diagnostics. Expert Review of Molecular Diagnostics, 2016, 16, 1067-1072.	1.5	5
46	Validation of digital pathology imaging for primary histopathological diagnosis. Histopathology, 2016, 68, 1063-1072.	1.6	180
47	PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology, 2016, 69, 177-186.	1.6	81
48	Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review. EBioMedicine, 2016, 10, 164-173.	2.7	43
49	Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). Biomolecular Detection and Quantification, 2016, 8, 29-32.	7.0	12
50	A multicentre validation of Metasin: a molecular assay for the intraoperative assessment of sentinel lymph nodes from breast cancer patients. Histopathology, 2016, 68, 875-887.	1.6	7
51	Locality Sensitive Deep Learning for Detection and Classification of Nuclei in Routine Colon Cancer Histology Images. IEEE Transactions on Medical Imaging, 2016, 35, 1196-1206.	5.4	921
52	Molecular testing for familial hypercholesterolaemia-associated mutations in a UK-based cohort: development of an NGS-based method and comparison with multiplex polymerase chain reaction and oligonucleotide arrays. Annals of Clinical Biochemistry, 2016, 53, 654-662.	0.8	9
53	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer, 2015, 15, 26.	1.1	49
54	Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer, 2015, 15, 117.	1.1	65

#	ARTICLE	IF	CITATIONS
55	Genomics driven-oncology: challenges and perspectives. BMC Cancer, 2015, 15, 141.	1.1	8
56	Liquid biopsy for cancer patients: Principles and practice. Pathogenesis, 2015, 2, 1-4.	0.8	31
57	KRAS Mutation Analysis by PCR: A Comparison of Two Methods. PLoS ONE, 2015, 10, e0115672.	1.1	20
58	Guidance for laboratories performing molecular pathology for cancer patients. Journal of Clinical Pathology, 2014, 67, 923-931.	1.0	169
59	Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model. BMC Research Notes, 2014, 7, 397.	0.6	14
60	Brachyury regulates proliferation of cancer cells via a p27Kip1-dependent pathway. Oncotarget, 2014, 5, 3813-3822.	0.8	13
61	Designing personalised cancer treatments. Journal of Controlled Release, 2013, 172, 405-409.	4.8	13
62	Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 27-37.	1.4	70
63	In vivo confocal microscopy and histopathology of the conjunctiva in trachomatous scarring and normal tissue: a systematic comparison. British Journal of Ophthalmology, 2013, 97, 1333-1337.	2.1	15
64	A Comparison of Methods for EGFR Mutation Testing in Non-Small Cell Lung Cancer. Diagnostic Molecular Pathology, 2013, 22, 190-195.	2.1	27
65	The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures. Anti-Cancer Drugs, 2012, 23, 65-69.	0.7	25
66	Pesticide exposure in farming and forestry and the risk of uveal melanoma. Cancer Causes and Control, 2012, 23, 141-151.	0.8	13
67	Principles of Cancer Cell Culture. Methods in Molecular Biology, 2011, 731, 13-26.	0.4	7
68	Atypical presentation of a hormonally active adrenocortical tumor in an adolescent leading to delayed diagnosis. Hormones, 2011, 10, 317-325.	0.9	1
69	Improved blood tests for cancer screening: general or specific?. BMC Cancer, 2011, 11, 499.	1.1	9
70	Cancer Biology. Methods in Molecular Biology, 2011, 731, 1-11.	0.4	23
71	The effect of pentamidine on melanoma ex vivo. Anti-Cancer Drugs, 2010, 21, 181-185.	0.7	42
72	Hormonal exposures and the risk of uveal melanoma. Cancer Causes and Control, 2010, 21, 1625-1634.	0.8	23

#	ARTICLE	IF	CITATIONS
73	Occupational exposure to electromagnetic fields and sex-differential risk of uveal melanoma. <i>Occupational and Environmental Medicine</i> , 2010, 67, 751-759.	1.3	12
74	Patterns of Expression of DNA Repair Genes and Relapse From Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 5211-5221.	3.2	53
75	The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. <i>Journal of Clinical Pathology</i> , 2010, 63, 1012-1020.	1.0	23
76	High-Throughput Screening of Natural Products for Cancer Therapy. <i>Planta Medica</i> , 2010, 76, 1080-1086.	0.7	56
77	An exploratory investigation of the influence of publication on translational medicine research. <i>Journal of Translational Medicine</i> , 2010, 8, 62.	1.8	1
78	Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. <i>Current Opinion in Pharmacology</i> , 2010, 10, 375-379.	1.7	89
79	Long-Term Follow-up after Submandibular Gland Transplantation in Severe Dry Eyes Secondary to Cicatrizing Conjunctivitis. <i>American Journal of Ophthalmology</i> , 2010, 150, 894-904.	1.7	66
80	Recurrence of treated ciliary body melanoma following trabeculectomy. <i>Clinical and Experimental Ophthalmology</i> , 2009, 37, 503-505.	1.3	13
81	Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2009, 9, 300.	1.1	33
82	Melanoma vaccines: The problems of local immunosuppression. <i>Human Immunology</i> , 2009, 70, 331-339.	1.2	27
83	How Could Contact Lens Wearers Be at Risk of Acanthamoeba Infection? A Review. <i>Journal of Optometry</i> , 2009, 2, 60-66.	0.7	44
84	Chemosensitivity and chemoresistance testing in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 39-43.	0.9	39
85	Screening Autoantibody Profiles in Systemic Rheumatic Disease with a Diagnostic Protein Microarray That Uses a Filtration-Assisted Nanodot Array Luminometric Immunoassay (NALIA). <i>Clinical Chemistry</i> , 2008, 54, 883-890.	1.5	18
86	Malignant transformation of iris melanocytoma to iris ring melanoma. <i>British Journal of Ophthalmology</i> , 2007, 91, 1571-1572.	2.1	11
87	Factors Affecting the Epidemiology of Acanthamoeba Keratitis. <i>Ophthalmic Epidemiology</i> , 2007, 14, 53-60.	0.8	76
88	Presence and phenotype of dendritic cells in uveal melanoma. <i>British Journal of Ophthalmology</i> , 2007, 91, 971-976.	2.1	23
89	A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 1093-1101.	0.7	94
90	Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. <i>Cytokine</i> , 2007, 40, 144-150.	1.4	65

#	ARTICLE	IF	CITATIONS
91	Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. <i>Experimental Eye Research</i> , 2006, 82, 798-806.	1.2	132
92	Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. <i>Anti-Cancer Drugs</i> , 2006, 17, 913-919.	0.7	20
93	The effect of imatinib mesylate (Glivec) on human tumor-derived cells. <i>Anti-Cancer Drugs</i> , 2006, 17, 649-655.	0.7	14
94	Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma. <i>Pathology and Oncology Research</i> , 2006, 12, 184-187.	0.9	11
95	Pilot studies of the effect of zoledronic acid (Zometa®) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. <i>Anti-Cancer Drugs</i> , 2005, 16, 969-976.	0.7	20
96	Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. <i>Anti-Cancer Drugs</i> , 2005, 16, 495-500.	0.7	10
97	Cancer cell adaptation to chemotherapy. <i>BMC Cancer</i> , 2005, 5, 78.	1.1	110
98	Treosulfan and gemcitabine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 329-330.	1.2	1
99	Occupational risks for uveal melanoma results from a case-control study in nine European countries. <i>Cancer Causes and Control</i> , 2005, 16, 437-447.	0.8	36
100	Presence and maturity of dendritic cells in melanoma lymph node metastases. <i>Journal of Pathology</i> , 2005, 207, 83-90.	2.1	21
101	Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. <i>Anti-Cancer Drugs</i> , 2004, 15, 849-860.	0.7	7
102	Ex vivo reversal of chemoresistance by tariquidar (XR9576). <i>Anti-Cancer Drugs</i> , 2004, 15, 861-869.	0.7	21
103	An Approach to Understanding the Transmission of <i>Mycobacterium leprae</i> Using Molecular and Immunological Methods: Results from the MILEP2 Study. <i>International Journal of Leprosy and Other Mycobacterial Diseases</i> , 2004, 72, 269.	0.3	23
104	The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1631-7.	1.9	12
105	Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. <i>Anti-Cancer Drugs</i> , 2003, 14, 397-403.	0.7	20
106	Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. <i>Anti-Cancer Drugs</i> , 2003, 14, 337-340.	0.7	56
107	Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). <i>Anti-Cancer Drugs</i> , 2003, 14, 369-375.	0.7	34
108	Chemosensitivity Testing as an Aid to Anti-Cancer Drug and Regimen Development. <i>Recent Results in Cancer Research</i> , 2003, 161, 119-125.	1.8	11

#	ARTICLE	IF	CITATIONS
109	Chemosensitivity of normal human trophoblasts evaluated by a newly developed ATP-based luminescence assay. <i>Anti-Cancer Drugs</i> , 2002, 13, 701-708.	0.7	3
110	Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. <i>Anti-Cancer Drugs</i> , 2002, 13, 625-630.	0.7	9
111	Chemosensitization of solid tumors by modulation of resistance mechanisms. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 634-40.	2.3	7
112	Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 641-7.	2.3	7
113	Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. <i>Investigative Ophthalmology and Visual Science</i> , 2002, 43, 2845-51.	3.3	13
114	Primary liposarcoma of the orbit: A clinicopathologic study of seven cases. <i>Annals of Diagnostic Pathology</i> , 2001, 5, 255-266.	0.6	83
115	Ex vivo activity of XR5000 against solid tumors. <i>Anti-Cancer Drugs</i> , 2000, 11, 471-478.	0.7	9
116	The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 2000, 11, 865-871.	0.7	14
117	Cell cycle and melanoma - two different tumours from the same cell type. , 2000, 191, 112-114.		20
118	Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. <i>Journal of Pathology</i> , 2000, 192, 174-181.	2.1	16
119	Correlation of Drug Response with the ATP Tumorchemosensitivity Assay in Primary FIGO Stage III Ovarian Cancer. <i>Gynecologic Oncology</i> , 2000, 77, 258-263.	0.6	90
120	Cell cycle and melanoma “ two different tumours from the same cell type. , 2000, 191, 112.		1
121	Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. <i>Anti-Cancer Drugs</i> , 1999, 10, 437-444.	0.7	49
122	ATP-based tumor chemosensitivity testing. <i>Anti-Cancer Drugs</i> , 1999, 10, 431-436.	0.7	23
123	Drug resistance in ovarian cancer “ the role of p53. <i>Pathology and Oncology Research</i> , 1998, 4, 97-102.	0.9	33
124	Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. <i>Anti-Cancer Drugs</i> , 1998, 9, 51-57.	0.7	107
125	Individualizing chemotherapy for solid tumors ??? is there any alternative?. <i>Anti-Cancer Drugs</i> , 1997, 8, 541-548.	0.7	45
126	The ex vivo chemosensitivity profile of choroidal melanoma. <i>Anti-Cancer Drugs</i> , 1997, 8, 756-762.	0.7	38

#	ARTICLE	IF	CITATIONS
127	Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. <i>Anti-Cancer Drugs</i> , 1996, 7, 630-635.	0.7	70
128	Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. <i>Breast Cancer Research and Treatment</i> , 1996, 41, 161-170.	1.1	23
129	Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures. <i>Anti-Cancer Drugs</i> , 1995, 6, 398-404.	0.7	32
130	C-Reactive Protein. <i>Chest</i> , 1995, 108, 1288-1291.	0.4	154
131	Comparison of MTT and ATP-based assays for the measurement of viable cell number. <i>Luminescence</i> , 1995, 10, 29-34.	1.3	201
132	The influence of age and sex on phagocyte chemiluminescence. <i>Luminescence</i> , 1995, 10, 41-48.	1.3	21
133	TCA-100 tumour chemosensitivity assay: Differences in sensitivity between cultured tumour cell lines and clinical studies. <i>Luminescence</i> , 1994, 9, 373-378.	1.3	37
134	TNF and Pneumonia. <i>Chest</i> , 1994, 106, 645.	0.4	0
135	Comparison of Salmeterol with Placebo in Mild Asthma: Effect on Peripheral Blood Phagocyte Function and Cytokine Levels. <i>International Archives of Allergy and Immunology</i> , 1994, 105, 181-184.	0.9	13
136	The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. <i>Anti-Cancer Drugs</i> , 1994, 5, 171-176.	0.7	19
137	Measurement of phagocyte chemiluminescence using a microtitre plate luminometer. <i>Luminescence</i> , 1989, 3, 67-70.	1.3	11
138	Use of a microtitre plate chemiluminescence reader to study surface phagocytosis by human monocytes. <i>Luminescence</i> , 1989, 3, 71-74.	1.3	6